EC
ELVN icon

EntryPoint Capital’s Enliven Therapeutics ELVN Stock Holding History

EntryPoint Capital’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-241
Closed -$5.63K – 760
2024
Q2 		$5.63K Sell
241
-9,269
-97% -$195K 0.01% 784
2024
Q1 		$167K Buy
+9,510
New +$146K 0.15% 169

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EntryPoint Capital's ELVN Position: Q3 2024 in Review

EntryPoint Capital sold out of Enliven Therapeutics (ELVN) in Q3 2024, closing a stake of 241 shares — an estimated $5.63K sold.

EntryPoint Capital first reported a position in ELVN in Q1 2024 and held it in 2 quarters. The position peaked at $167K in Q1 2024. 102 funds tracked by Wall St. Rank hold ELVN as of Q3 2024.

  • EntryPoint Capital reported no remaining Enliven Therapeutics position as of Q3 2024 after selling out during the quarter.
  • EntryPoint Capital sold 241 Enliven Therapeutics shares in Q3 2024, an estimated $5.63K.
  • EntryPoint Capital first reported a position in Enliven Therapeutics in Q1 2024 and held it in 2 quarters.
  • EntryPoint Capital's Enliven Therapeutics position peaked at $167K in Q1 2024.
  • 102 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2024.

Based on EntryPoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.